Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

LDH-H

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

LDH-H	Melanoma	LDH-H	Melanoma	PD-L1 inhibitor Sensitive: B - Late Trials PD-L1 inhibitor Sensitive : B	PD-L1 inhibitor Sensitive: B - Late Trials PD-L1 inhibitor Sensitive : B
LDH-H	Melanoma	LDH-H	Melanoma	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials trametinib + dabrafenib + PDR001 Sensitive : B	trametinib + dabrafenib + PDR001 Sensitive: B - Late Trials trametinib + dabrafenib + PDR001 Sensitive : B
LDH-H	Gastric Cancer	LDH-H	Gastric Cancer	ramucirumab Resistant: C3 – Early Trials ramucirumab Resistant : C3	ramucirumab Resistant: C3 – Early Trials ramucirumab Resistant : C3
LDH-H	Melanoma	LDH-H	Melanoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
LDH-H	Uveal Melanoma	LDH-H	Uveal Melanoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
LDH-H	Uveal Melanoma	LDH-H	Uveal Melanoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
LDH-H	Uveal Melanoma	LDH-H	Uveal Melanoma	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3
LDH-H	Triple Negative Breast Cancer	LDH-H	Triple Negative Breast Cancer	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
LDH-H	HER2 Positive Breast Cancer	LDH-H	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Resistant: C3 – Early Trials ado-trastuzumab emtansine Resistant : C3	ado-trastuzumab emtansine Resistant: C3 – Early Trials ado-trastuzumab emtansine Resistant : C3
LDH-H	Melanoma	LDH-H	Melanoma	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3	PD1 inhibitor Resistant: C3 – Early Trials PD1 inhibitor Resistant : C3
LDH-H	Melanoma	LDH-H	Melanoma	camrelizumab + rivoceranib Resistant: C3 – Early Trials camrelizumab + rivoceranib Resistant : C3	camrelizumab + rivoceranib Resistant: C3 – Early Trials camrelizumab + rivoceranib Resistant : C3
LDH-H	Lymphoma	LDH-H	Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3